Results 41 to 50 of about 14,826 (163)
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8057-8071, September 2026.ABSTRACT Background In the SELECT trial, semaglutide reduced major adverse cardiovascular outcomes (MACE) in individuals with overweight or obesity and established cardiovascular disease (CVD) but without diabetes. However, real‐world cardiovascular event rates in comparable populations remain uncharacterised.
Viveca Ritsinger +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, Volume 28, Issue 9, Page 8004-8015, September 2026.ABSTRACT Aims To assess progression of insulin deficiency and resistance in diabetes, the stability of cluster‐based subgrouping, and the association between steatotic liver disease (SLD), liver fibrosis (LF), and tissue insulin resistance. Materials and Methods Participants from a regional diabetes register were studied within 3 years from diagnosis ...
Aleksi Laitinen +10 more
wiley +1 more source
EZETIMIBE IN HYPERCHOLESTEROLAEMIA
International Journal of Clinical Practice, 2002 SUMMARYEzetimibe is the first member of a new class of selective cholesterol absorption inhibitors, compounds that effectively block intestinal absorption of dietary and biliary cholesterol, without affecting absorption of fat soluble vitamins or triglycerides.
openaire +2 more sources
Autophagy in MASLD: A Metabolic and Precision Medicine Perspective
Liver International, Volume 46, Issue 9, September 2026.ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is the most common chronic liver condition worldwide and a major contributor to cirrhosis and hepatocellular carcinoma (HCC). While metabolic triggers such as obesity and insulin resistance are key drivers of MASLD, growing evidence has identified defects in intracellular quality
Alessandra Cazzaniga +4 more
wiley +1 more source
Journal of the Turkish Chemical Society, Section A: Chemistry, 2020 Fixed dose combinations of ezetimibe and rosuvastatin are well known to provide significantly superior efficacy to rosuvastatin alone in lowering total cholesterol, and triglyceride levels.
Sevinç KURBANOĞLU +6 more
doaj
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 475-483, August 2026.Statin‐associated muscle symptoms (SAMS) are frequent adverse effects of statin therapy and have been hypothesized to result from impaired coenzyme Q10 (CoQ10) biosynthesis. Although genetic determinants of CoQ10 levels have been reported, genome‐wide association studies (GWASs) conducted specifically in statin users are lacking. Moreover, direct CoQ10
Da Hoon Lee +6 more
wiley +1 more source
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 492-500, August 2026.Coproporphyrin I (CPI) is an established endogenous biomarker for detecting drug–drug interactions (DDIs) involving the hepatic uptake transporter Organic Anion Transporting Polypeptide 1B1 (OATP1B1, gene SLCO1B1). While CPI has been extensively studied in healthy volunteers using controlled pre‐ and post‐OATP1B1‐inhibitor sampling, its applicability ...
Leila Potzel +9 more
wiley +1 more source
Population Genomics Insights into Pharmacogenomic Differentiation Between East Asians and Europeans
Clinical Pharmacology &Therapeutics, Volume 120, Issue 2, Page 510-519, August 2026.Genetic variation contributes substantially to interindividual and interpopulation differences in drug response, yet most pharmacogenomic studies remain biased toward European populations. Here, we systematically assessed pharmacogenomic variation across East Asians (EAS) and Europeans (EUR) using public genomic datasets and investigated the potential ...
Sihan Chen, Hongpu Chen, Shuhua Xu
wiley +1 more source
Lipids in Health and Disease, 2018 Background The utility of ezetimibe in preventing cardiovascular outcomes remains controversial. To guide future assessments of the effectiveness of ezetimibe in routine care, we evaluated how this medication has been prescribed to high-risk older adults
Kristin K. Clemens +3 more
doaj +1 more source
Clinical and Translational Discovery, Volume 6, Issue 4, August 2026.Multi‐endpoint clinical trials face long‐standing statistical challenges. Vector‐based comparison (VBC) decomposes endpoints into orthogonal components. Applied to five clinical trials, it reduced confidence‐interval widths by about 50%, indicating higher statistical power, without altering the clinical meaning of endpoints.
Maria Kokkali, Vangelis D. Karalis
wiley +1 more source